Analysis by GenericsWeb Reveals More Than a Third of Granted or Pending SPCs are Potentially Invalid

Following the recent Medeva rulings, GenericsWeb, the leader in established pharmaceutical patent analysis and searching, decided to verify every SPC to determine their potential invalidity. The result of this analysis is that more than a third of granted or pending SPCs have questionable validity on the basis of these recent rulings. Sydney, Australia (PRWEB) June 27, 2012 After the recent decisions handed down by the Court of Justice of the European Union (CJEU) in Medeva (C 322/10) and the related Georgetown (C-422/10), Queensland (C-630/10), Yeda (C 518/10) and Daiichi (C-6/11) referra
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations